Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-acting subcutaneous insulin added to standard treatment for pediatric diabetic ketoacidosis
IRCT20201125049485N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of human insulin in diabetic ketoacidosis (DKA) (3 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoint: Time to exit the acute phase of diabetic ketoacidosis. Started Nov 2020; status: completed.
02
Drugs
human insulin
03
Conditions
diabetic ketoacidosis (DKA)
Beyond the preview
Go deeper on IRCT20201125049485N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201125049485N1.